Published in J Gen Intern Med on July 01, 2011
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
A prospective study of statin drug use and lower urinary tract symptoms in older men. Am J Epidemiol (2013) 1.75
Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int (2012) 1.52
Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol (2016) 0.84
Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey. Urology (2012) 0.82
The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.82
Re: Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Urol (2012) 0.75
Associations between the severity of obstructive lower urinary tract symptoms and care-seeking behavior in rural Africa: A cross-sectional survey from Uganda. PLoS One (2017) 0.75
Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume. PLoS One (2015) 0.75
Is there room for behavioral and modifiable health-related targets in the lower urinary tract symptoms' scenario. World J Urol (2017) 0.75
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol (1992) 13.63
Urologic diseases in America project: benign prostatic hyperplasia. J Urol (2005) 4.09
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
The association of skin color with blood pressure in US blacks with low socioeconomic status. JAMA (1991) 3.29
The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved (2010) 2.44
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res (1998) 1.84
Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology (2002) 1.83
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol (2002) 1.71
Patient misunderstanding of the individual questions of the American Urological Association symptom score. J Urol (2008) 1.46
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol (2006) 1.42
Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer (2006) 1.37
The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology (2000) 1.29
Race and socioeconomic status are independently associated with benign prostatic hyperplasia. J Urol (2008) 1.22
Race and the validity of self-reported cancer screening behaviors: development of a conceptual model. Prev Med (2008) 1.21
Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol (2000) 1.16
An assessment of the comprehension of the American Urological Association Symptom Index. J Urol (1998) 1.13
Knowledge, attitudes and beliefs of women about the importance of prostate cancer screening. J Natl Med Assoc (2005) 1.12
Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate (1997) 1.00
Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med (2008) 0.96
Assessment of the performance of the American Urological Association symptom score in 2 distinct patient populations. J Urol (2008) 0.95
Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml. J Urol (2000) 0.91
Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology (1999) 0.90
Influence of sociodemographic and health status variables on the American Urological Association symptom scores in patients with lower urinary tract symptoms. Urology (2001) 0.86
Poorly numerate patients in an inner city hospital misunderstand the American Urological Association symptom score. Urology (2009) 0.84
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Urologic diseases in America project: urolithiasis. J Urol (2005) 4.90
Merging and emerging cohorts: not worth the wait. Nature (2007) 4.66
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
False-positive results in cancer epidemiology: a plea for epistemological modesty. J Natl Cancer Inst (2008) 3.72
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc (2005) 3.67
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst (2006) 3.36
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
The landscape of recombination in African Americans. Nature (2011) 3.06
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst (2004) 2.63
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved (2010) 2.44
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
A further plea for adherence to the principles underlying science in general and the epidemiologic enterprise in particular. Int J Epidemiol (2009) 2.35
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Comparing diabetes prevalence between African Americans and Whites of similar socioeconomic status. Am J Public Health (2007) 2.24
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol (2006) 2.02
Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01
The Björk-Shiley convexo-concave heart valve experience from the perspective of the supervisory panel. Am J Cardiol (2013) 2.00
A rebuttal: secret ties to industry and conflicting interests in cancer research. Am J Ind Med (2007) 1.99
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood (2010) 1.98
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol (2005) 1.97
Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev (2009) 1.90
Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst (2012) 1.88
Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control (2008) 1.86
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther (2002) 1.82
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol (2011) 1.72
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
A cohort mortality study among titanium dioxide manufacturing workers in the United States. J Occup Environ Med (2003) 1.70
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol (2004) 1.68
Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst (2003) 1.68
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.66
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol (2010) 1.64
Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol (2010) 1.60
Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer (2004) 1.60
Risk of lung cancer and residential radon in China: pooled results of two studies. Int J Cancer (2004) 1.60
Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int (2008) 1.59
Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry. Cancer Res (2011) 1.59
Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int (2010) 1.57
Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology (2012) 1.56
Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol (2002) 1.54
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 1.54
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol (2013) 1.53
Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology (2012) 1.53
Estimating nutrient intake from a food frequency questionnaire: incorporating the elements of race and geographic region. Am J Epidemiol (2009) 1.53
Lung cancer risk among smokers of menthol cigarettes. J Natl Cancer Inst (2011) 1.50